Doyle Anthony 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Dec 18, 2023
Insider Transaction Report
Form 4
Doyle Anthony
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2023-12-14$6.43/sh−5,475$35,204→ 229,926 total - Award
Common Stock
2023-12-14+34,000→ 235,401 total - Award
Emp. Stock Option (Right to Buy)
2023-12-14+158,500→ 158,500 totalExercise: $6.43From: 2024-12-14Exp: 2033-12-14→ Common Stock (158,500 underlying)
Footnotes (3)
- [F1]Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- [F2]Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.
- [F3]Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.